Risk factors for second primary malignancies following thyroid cancer: a nationwide cohort study

xlomafota13 shared this article with you from Inoreader Risk factors for second primary malignancies following thyroid cancer: a nationwide cohort study Via radioactive iodine Eur J Endocrinol. 2022 Mar 1:EJE-21-1208. doi: 10.1530/EJE-21-1208. Online ahead of print. ABSTRACT OBJECTIVE: Thyroid cancer survivors have a high risk of second primary malignancies (SPMs). We aimed to evaluate the site-specific incidence, prognosis, and risk factors for metachronous SPMs following thyroid cancer. DESIGN: A nationwide cohort study Methods: This study included data from the Korea National Health Insurance Service (between 2002 and 2018). Exposure to diagnost ic radiation was defined by the number of computed tomography (CT) and positron emission tomography-CT scans after the index date. A cumulative radioactive iodine (RAI) dose >100 mCi was considered high-dose RAI. RESULTS: During the median six years of follow-up, among 291,640 patients, 13,083 (4·5%) developed SPMs. Thyroid cancer survivors had a 26% increased risk of SPMs compared with the general population (SIR, 1·26; 95% CI, 1·22-1·29). Furthermore, those with SPMs had a significantly poorer survival rate than those without SPMs (HR, 11·85; 95% CI, 11·21-12·54; p<0·001). Significantly elevated risks were observed in myeloid leukemia and 13 solid cancer sites: lip, salivary gland, small intestine, larynx, lung, mediastinum and pleura, mesothelium, breast, corpus uteri, ovary, prostate, kidney, and bladder. Frequent diagnostic medical radiation exposure and high-dose RAI therapy were independent risk factors for several SPMs, including the cancer of salivary gl and, lung, mediastinum and pleura, breast, kidney, and bladder, as well as myeloid leukemia. CONCLUSIONS: Frequent diagnostic radiation exposure and high-dose RAI therapy are independent risk factors for SPM following thyroid cancer. Clinicians need to consider for minimizing unnecessary diagnostic radiation exposure and administering a high dose RAI only when justified in patients with thyroid cancer. PMID:35286279 | DOI:10.1530/EJE-21-1208 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.